Insights

Innovative Platform Vascugen's exclusive patent portfolio and advanced platform technology for functional blood vessel restoration present opportunities for strategic partnerships, licensing, or joint ventures to expand their therapeutic applications across various medical sectors.

Emerging Market Presence With a growing focus on regenerative medicine and vascular therapies, Vascugen is well-positioned to capitalize on increasing demand for innovative treatments, offering potential for sales expansion into biotech and pharmaceutical partners.

Research and Diagnostics Their rights covering research, diagnostics, and bioengineering applications open avenues to offer specialized products or services to research institutions and diagnostic companies seeking vascular regeneration solutions.

Funding and Growth Having secured $10 million in funding and generating up to $10 million in revenue, Vascugen demonstrates financial stability and growth potential, making it an attractive partner or client for providers of research tools and biotech infrastructure.

Technology Stack Synergies Utilizing widely adopted digital tools like Squarespace and Google Fonts indicates an emphasis on modern digital presence, suggesting opportunities to collaborate on digital marketing, web development, or software solutions to enhance their outreach.

Similar companies to Vascugen

Vascugen Tech Stack

Vascugen uses 8 technology products and services including Open Graph, Squarespace, Squarespace Commerce, and more. Explore Vascugen's tech stack below.

  • Open Graph
    Content Management System
  • Squarespace
    Content Management System
  • Squarespace Commerce
    E-commerce
  • Google Workspace
    Email
  • Google Fonts API
    Font Scripts
  • Element UI
    Javascript Frameworks
  • Priority Hints
    Performance
  • HSTS
    Security

Media & News

Vascugen's Email Address Formats

Vascugen uses at least 1 format(s):
Vascugen Email FormatsExamplePercentage
FLast@vascugen.comJDoe@vascugen.com
50%
FLast@vascugen.comJDoe@vascugen.com
50%

Frequently Asked Questions

Where is Vascugen's headquarters located?

Minus sign iconPlus sign icon
Vascugen's main headquarters is located at 5602 Research Park Blvd, Madison, Wisconsin 53719, US. The company has employees across 1 continents, including North America.

What is Vascugen's official website and social media links?

Minus sign iconPlus sign icon
Vascugen's official website is vascugen.com and has social profiles on LinkedInCrunchbase.

What is Vascugen's SIC code NAICS code?

Minus sign iconPlus sign icon
Vascugen's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Vascugen have currently?

Minus sign iconPlus sign icon
As of October 2025, Vascugen has approximately 11 employees across 1 continents, including North America. Key team members include Chief Executive Officer: D. M.Assoc. Director R&d: M. G.Project Manager Scientist & Intellectual Property Manager: K. A.. Explore Vascugen's employee directory with LeadIQ.

What industry does Vascugen belong to?

Minus sign iconPlus sign icon
Vascugen operates in the Biotechnology Research industry.

What technology does Vascugen use?

Minus sign iconPlus sign icon
Vascugen's tech stack includes Open GraphSquarespaceSquarespace CommerceGoogle WorkspaceGoogle Fonts APIElement UIPriority HintsHSTS.

What is Vascugen's email format?

Minus sign iconPlus sign icon
Vascugen's email format typically follows the pattern of FLast@vascugen.com. Find more Vascugen email formats with LeadIQ.

How much funding has Vascugen raised to date?

Minus sign iconPlus sign icon
As of October 2025, Vascugen has raised $10M in funding. The last funding round occurred on Oct 11, 2019 for $10M.

When was Vascugen founded?

Minus sign iconPlus sign icon
Vascugen was founded in 2017.

Vascugen

Biotechnology ResearchUnited States11-50 Employees

Vascugen is a regenerative medicine company engaged in the development of advanced therapies to treat incurable conditions caused by loss or degeneration of blood vessels. The company has exclusive, worldwide rights to a broad patent portfolio for its platform technology that enables the functional restoration of blood vessels in any organ or tissue, as well as rights covering related products and services for research, diagnostics, therapeutics, tissue engineering, organoid and 3D bio-printing applications. Driven by innovation and a team of scientific and clinical thought leaders, Vascugen was founded by Dr. Mervin C. Yoder, a pioneer and noted expert in the field of vascular stem cell biology.

Section iconCompany Overview

Headquarters
5602 Research Park Blvd, Madison, Wisconsin 53719, US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $10M

    Vascugen has raised a total of $10M of funding over 2 rounds. Their latest funding round was raised on Oct 11, 2019 in the amount of $10M.

  • $1M$10M

    Vascugen's revenue is estimated to be in the range of $1M$10M

Section iconFunding & Financials

  • $10M

    Vascugen has raised a total of $10M of funding over 2 rounds. Their latest funding round was raised on Oct 11, 2019 in the amount of $10M.

  • $1M$10M

    Vascugen's revenue is estimated to be in the range of $1M$10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.